United Therapeutics Corp
Atidarymo kaina
SektoriusSveikatos priežiūra
551.4 -0.19
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
542.36
Max
554.59
Pajamos | -89M 275M |
|---|---|
Pardavimai | -8.7M 782M |
P/E Sektoriaus vid. | 20.136 49.052 |
Pelnas, tenkantis vienai akcijai | 5.82 |
Pelno marža | 35.176 |
Darbuotojai | 1,400 |
EBITDA | -176M 348M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +22.53% upside |
Kitas uždarbis | 2026-07-29 |
|---|
Rinkos kapitalizacija | -1.5B 23B |
|---|---|
Ankstesnė atidarymo kaina | 551.59 |
Ankstesnė uždarymo kaina | 551.4 |
Naujienos nuotaikos
By Acuity
48%
52%
157 / 342 reitingas Healthcare
United Therapeutics Corp Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.